New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
06:30 EDTCOV, MYL, MDT, VRX, ABTObama calls on Congress to end inversion deals, NY Times reports
President Obama yesterday called on Congress to eliminate tax inversion loopholes, and criticized companies that have taken advantage of the loopholes, according to The New York Times. Meanwhile, there is a "growing consensus" among lawmakers of both parties that inversions should be curtailed, although the parties disagree on how to do so, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
News For MYL;ABT;MDT;COV;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 14, 2014
09:38 EDTVRXJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
16:35 EDTMDTMedtronic study reveals heart rhythm disorders in patients with ESRD
Subscribe for More Information
14:50 EDTMDTLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTMDTLonestar capital to shut down, DJ reports
Subscribe for More Information
13:27 EDTCOV, MDTMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
09:33 EDTVRXZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:38 EDTMYLBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
07:23 EDTVRXValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
10:09 EDTVRXActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
07:23 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 23, December is at 20, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
06:22 EDTVRXZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
16:24 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
15:46 EDTVRXPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
08:32 EDTVRXValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
07:24 EDTMDT, COVMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:10 EDTMDTMedtronic announces Japanese approval, launch of Evera MRI SureScan ICD
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information
November 9, 2014
13:26 EDTVRXAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use